NASDAQ:CLRB Cellectar Biosciences (CLRB) Stock Price, News & Analysis $2.08 -0.02 (-0.95%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.06▼$2.1550-Day Range$1.86▼$3.0252-Week Range$1.82▼$4.45Volume286,233 shsAverage Volume1.07 million shsMarket Capitalization$74.57 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cellectar Biosciences alerts: Email Address Cellectar Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside861.5% Upside$20.00 Price TargetShort InterestHealthy7.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.57) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.10 out of 5 starsMedical Sector588th out of 910 stocksPharmaceutical Preparations Industry270th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectar Biosciences has received no research coverage in the past 90 days.Read more about Cellectar Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.35% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 10.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLRB. Previous Next 3.3 News and Social Media Coverage News SentimentCellectar Biosciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cellectar Biosciences this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Cellectar Biosciences is held by institutions.Read more about Cellectar Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.57) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Cellectar Biosciences Stock (NASDAQ:CLRB)Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Read More CLRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLRB Stock News HeadlinesAugust 26, 2024 | stockhouse.comIopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's MacroglobulinemiaAugust 26, 2024 | globenewswire.comIopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's MacroglobulinemiaSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 23, 2024 | globenewswire.comCellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from NasdaqAugust 18, 2024 | ca.finance.yahoo.comCLRB Sep 2024 5.000 callAugust 17, 2024 | ca.finance.yahoo.comCLRB Sep 2024 2.500 callAugust 15, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Cellectar Biosciences (CLRB)August 13, 2024 | globenewswire.comCellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate UpdateSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 12, 2024 | msn.comCellectar Biosciences Q2 2024 Earnings PreviewAugust 8, 2024 | globenewswire.comUPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024July 30, 2024 | ca.finance.yahoo.comCLRB Aug 2024 5.000 putJuly 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Improved Financial OutlookJuly 25, 2024 | seekingalpha.comCellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call TranscriptJuly 23, 2024 | benzinga.comCancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer StudyJuly 23, 2024 | seekingalpha.comCellectar: WM Treatment Data Leads To A Few Regulatory MilestonesJuly 23, 2024 | msn.comCellectar falls after updating pivotal data for lead assetJuly 23, 2024 | globenewswire.comCellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 MonthsSee More Headlines Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLRB CUSIPN/A CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$28.00 Low Stock Price Target$12.00 Potential Upside/Downside+861.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,980,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-200.45% Debt Debt-to-Equity RatioN/A Current Ratio2.54 Quick Ratio2.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-5.78Miscellaneous Outstanding Shares35,849,000Free Float34,523,000Market Cap$74.57 million OptionableOptionable Beta0.99 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. James V. Caruso (Age 65)President, CEO & Director Comp: $1.14MMr. Chad J. Kolean CPA (Age 60)VP, CFO & Secretary Comp: $711.23kMr. Jarrod Longcor (Age 51)Chief Operating Officer Comp: $854.24kMr. Darrell Shane Lea (Age 50)Chief Commercial Officer Dr. Andrei Shustov M.D. (Age 52)Senior Vice President of Medical Key CompetitorsOcuphire PharmaNASDAQ:OCUPMillendo TherapeuticsNASDAQ:MLNDAtea PharmaceuticalsNASDAQ:AVIRAC ImmuneNASDAQ:ACIUAlimera SciencesNASDAQ:ALIMView All CompetitorsInstitutional OwnershipNantahala Capital Management LLCSold 40,000 shares on 8/20/2024Ownership: 5.114%Coastal Bridge Advisors LLCSold 5,000 shares on 8/16/2024Ownership: 0.031%XTX Topco LtdBought 51,413 shares on 8/12/2024Ownership: 0.177%AIGH Capital Management LLCBought 231,270 shares on 8/7/2024Ownership: 8.469%Rosalind Advisors Inc.Bought 2,084,138 shares on 7/12/2024Ownership: 7.547%View All Institutional Transactions CLRB Stock Analysis - Frequently Asked Questions How have CLRB shares performed this year? Cellectar Biosciences' stock was trading at $2.77 at the beginning of 2024. Since then, CLRB shares have decreased by 24.9% and is now trading at $2.08. View the best growth stocks for 2024 here. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $0.10. When did Cellectar Biosciences' stock split? Cellectar Biosciences's stock reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Cellectar Biosciences' major shareholders? Cellectar Biosciences' top institutional shareholders include AIGH Capital Management LLC (8.47%), Rosalind Advisors Inc. (7.55%), Nantahala Capital Management LLC (5.11%) and XTX Topco Ltd (0.18%). View institutional ownership trends. How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF) and This page (NASDAQ:CLRB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
